Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 89.1%

Gross margin was 89.1% in Q1 FY2026, down 8.5 pp from a year earlier. On a trailing-twelve-month basis it was 98.0%, up 0.8 pp year over year. Over 3 fiscal years it narrowed by 0.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
89.1%-9.9 pp QoQ
Last fiscal yearDec 2025
94.2%-2.3 pp YoY
LTMMar 2026
98.0%+0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.5 pp——
1 year-2.3 pp——
3 years-0.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
94.2%
Year-over-year change
-2.3pp

Gross Margin vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 gross margin of 98.0% is the highest of the 4 companies compared; the peer median is 80.0%.
  • Its year-over-year change of +0.8 pp is the 3rd highest of 4, against a peer median of +3.7 pp.
  • Over three fiscal years its change of -0.9 pp compares with a peer median of +85.4 pp.
LCTX Competitors Peer median
Gross Margin for LCTX and competitors
Company Period LTM level YoY 3-year change
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
MESOMesoblast LimitedLTM Jun 202680.0% +288.5 pp+716.3 pp
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
Peer median (excluding LCTX) 80.0%+3.7 pp+85.4 pp

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.